CHINA PHARMA HOLDINGS, INC. Financing Receivable Modification To Total Financing Receivables Excluding Accrued Interest Percent
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Financing Receivable Modification To Total Financing Receivables Excluding Accrued Interest Percent of 2.00% for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Notes › Receivables › and Others
us-gaap:FinancingReceivableModificationToTotalFinancingReceivablesExcludingAccruedInterestPercent · last filed 2023-08-14
- 2023-06-30: Financing Receivable Modification To Total Financing Receivables Excluding Accrued Interest Percent 6 month 2.00%.
| Period end | Financing Receivable Modification To Total Financing Receivables Excluding Accrued Interest Percent 6 month |
|---|---|
| 2023-06-30 | 2.00% 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |